Lipid Panel Interpretation

ApoB, LDL-C, Non-HDL-C, and Triglycerides: How the Four Markers Compare

A standard lipid panel hands you several numbers. They don't always agree — and when they don't, the difference matters more than any single value.

If you've had bloodwork done, you've likely seen four numbers side by side: LDL cholesterol, non-HDL cholesterol, triglycerides, and — if you asked for it specifically — ApoB. They sound like they're measuring the same thing. They're not, and understanding the difference is often the key to reading your own risk correctly.

What each marker actually measures

MarkerWhat it measuresWhat it missesWhy it matters
ApoB The number of atherogenic (artery-damaging) particles in circulation — every LDL, VLDL, and IDL particle carries exactly one ApoB molecule Doesn't separately report cholesterol content per particle The most direct estimate of particle burden — the driver of plaque formation
LDL-C The mass of cholesterol carried inside LDL particles Particle number, and remnant (VLDL/IDL) particles Familiar, guideline-anchored treatment target — but can underestimate risk when particles are small and cholesterol-poor
Non-HDL-C All cholesterol carried in atherogenic particles (LDL + VLDL + remnants), calculated as total cholesterol minus HDL-C Particle number specifically A stronger surrogate than LDL-C alone when triglycerides are elevated
Triglycerides Circulating triglyceride-rich lipoproteins Direct particle burden; not itself an atherogenic-particle count A signal of metabolic health and remnant-particle burden, not a standalone atherosclerosis target

The analogy

Think of LDL-C as the amount of cargo on the road, and ApoB as the number of vehicles carrying it. Two people can be hauling the same total cargo — but the one using more, smaller vehicles has more opportunities for a collision. For arteries, the number of particles is often what predicts trouble, not just how much cholesterol they're carrying.

Reference frame: standard ranges vs. guideline targets

Each marker also has its own target ladder, and the target depends on overall cardiovascular risk category — not one-size-fits-all.

MarkerModerate riskHigh riskVery-high risk
LDL-C<100 mg/dL<70 mg/dL (≥50% reduction)<55 mg/dL (≥50% reduction)
ApoB<100 mg/dL<80 mg/dL<65 mg/dL
Non-HDL-C<130 mg/dL<100 mg/dL<85 mg/dL

Source: 2019 ESC/EAS Dyslipidaemia Guidelines (ehz455); reaffirmed unchanged by the 2025 ESC/EAS Focused Update (Mach et al., Eur Heart J 2025, ehaf190) — the 2025 update changed how risk category is calculated (SCORE2/SCORE2-OP), not the targets themselves.

Triglycerides don't carry a risk-tiered guideline target the way LDL-C, ApoB, and non-HDL-C do — but a fasting level under 150 mg/dL is the standard cut, with values under 100 mg/dL generally considered a more favorable, longevity-oriented range.

Why the numbers can disagree

ApoB and LDL-C usually move together. When they don't — a pattern called discordance — it's usually because the LDL particles themselves have changed character: more of them, each carrying less cholesterol. That pattern shows up especially often alongside elevated triglycerides, insulin resistance, metabolic syndrome, diabetes, or a very low LDL-C that looks reassuring on its own.

In that setting, LDL-C can understate how many atherogenic particles are actually circulating — which is exactly why guidelines increasingly point to ApoB as the more informative measure of particle burden when the picture is discordant.

A practical hierarchy

When the four markers don't tell a single clean story, this is roughly how they're weighted in practice:

  1. ApoB — the most direct read on atherogenic particle burden, especially useful when the picture is discordant
  2. Non-HDL-C — a strong, widely available surrogate when triglycerides are elevated
  3. LDL-C — the most familiar number for tracking treatment over time
  4. Triglycerides — context on metabolic health and remnant burden, not a standalone target

None of these replace the others outright — most physicians look at the full panel together, not any single number in isolation.

What this means for you

If your LDL-C has always come back "normal" but you also carry elevated triglycerides, insulin resistance, or a family history of early heart disease, it may be worth discussing an ApoB (or non-HDL-C, which any standard panel can calculate) with your physician — not because your standard panel failed you, but because these markers each answer a slightly different question, and a fuller picture sometimes changes the conversation about your risk.

Standard report · $49

A CardioIQ report reads your ApoB, LDL-C, non-HDL-C, and triglycerides together — against the same longevity-optimal targets referenced here — so you have a physician-grade summary to bring to your own doctor.

See your full lipid picture →

Related reading: the ApoB Guide (start here if ApoB is new to you), Standard vs. Advanced Lipid Panel (deciding what to test), and "Normal" vs. Optimal Cholesterol.

This article explains how lipid markers are interpreted in general and is not a diagnosis or personalized medical advice. A CardioIQ report is a reference-frame starting point, not a diagnosis — always discuss your own results and any decisions with your physician, who has your full clinical picture.
Dr. Tea Gamezardashvili, MD, PhD, MHA, FACC Preventive cardiologist & lipidologist · President, Georgian Atherosclerosis Association · National Coordinator, EAS Lipid Clinic Network